hrcak mascot   Srce   HID

Alcoholism and psychiatry research : Journal on psychiatric research and addictions, Vol.53 No.1 Lipanj 2017.

Pregledni rad
https://doi.org/10.20471/apr.2017.53.01.04

The role of thrombocyte serotonin system and some thrombocyte characteristics in treatment of depressive patients with cardiovascular diseases

Lidija Kostanjšak ; Acute Psychiatric Unit, University Hospital Campus, Ennis, Co. Clare, Ireland
Davor Zdunić ; Department of Psychiatry, Sestre milosrdnice University Hospital Center, Zagreb, Croatia

Puni tekst: engleski, pdf (414 KB) str. 33-44 preuzimanja: 112* citiraj
APA 6th Edition
Kostanjšak, L. i Zdunić, D. (2017). The role of thrombocyte serotonin system and some thrombocyte characteristics in treatment of depressive patients with cardiovascular diseases. Alcoholism and psychiatry research, 53 (1), 33-44. https://doi.org/10.20471/apr.2017.53.01.04
MLA 8th Edition
Kostanjšak, Lidija i Davor Zdunić. "The role of thrombocyte serotonin system and some thrombocyte characteristics in treatment of depressive patients with cardiovascular diseases." Alcoholism and psychiatry research, vol. 53, br. 1, 2017, str. 33-44. https://doi.org/10.20471/apr.2017.53.01.04. Citirano 22.11.2018.
Chicago 17th Edition
Kostanjšak, Lidija i Davor Zdunić. "The role of thrombocyte serotonin system and some thrombocyte characteristics in treatment of depressive patients with cardiovascular diseases." Alcoholism and psychiatry research 53, br. 1 (2017): 33-44. https://doi.org/10.20471/apr.2017.53.01.04
Harvard
Kostanjšak, L., i Zdunić, D. (2017). 'The role of thrombocyte serotonin system and some thrombocyte characteristics in treatment of depressive patients with cardiovascular diseases', Alcoholism and psychiatry research, 53(1), str. 33-44. doi: https://doi.org/10.20471/apr.2017.53.01.04
Vancouver
Kostanjšak L, Zdunić D. The role of thrombocyte serotonin system and some thrombocyte characteristics in treatment of depressive patients with cardiovascular diseases. Alcoholism and psychiatry research [Internet]. 2017 [pristupljeno 22.11.2018.];53(1):33-44. doi: https://doi.org/10.20471/apr.2017.53.01.04
IEEE
L. Kostanjšak i D. Zdunić, "The role of thrombocyte serotonin system and some thrombocyte characteristics in treatment of depressive patients with cardiovascular diseases", Alcoholism and psychiatry research, vol.53, br. 1, str. 33-44, 2017. [Online]. doi: https://doi.org/10.20471/apr.2017.53.01.04

Sažetak
Serotonin has an important role in the development of depressive disorders. Bearing in mind that direct testing of central nervous system is unavailable to researchers due to the inability to reach the samples, ever greater attention is given to the peripheral systems that can help us diagnose and detect changes of the disease, but also follow the course of its treatment and recovery. Thrombocyte is a blood cell that contains serotonin lodged in its delta granules. Thrombocyte serotonin system is similar, although not the same as the serotonin system in central nervous system. The most important differences are that in thrombocytes, serotonin is broken down by the enzyme monoaminooxidase B (MAO-B), while that function in neuron is carried out by monoaminooxidase A (MAO-A) and that a thrombocyte cannot synthetize serotonin itself, because it lacks tryptophan hydroxylase. Nowadays, in the treatment of depressive disorders, mostly the selective inhibitors of serotonin uptake (SIPPS) are being used. The research has proved that therapy with those medications changes the concentration of serotonin in thrombocytes and changes the values of some thrombocyte indices. The thrombocyte serotonin is a powerful vasoconstrictor, which increases the cardiovascular risk and the probability of thrombogenesis. The mean volume of thrombocytes (MPV) is a positive index of thrombocyte activity and the increase of MPV represents an independent risk factor for the development of cardiovascular diseases. It is of enormous significance to recognize the depression in patients who suffer from cardiovascular diseases. Depression interferes with the recovery of those patients, because it reduces the personal engagement in it and disturbs patients’ compliance and the motivation for treatment. Besides the fact that the treatment with SIPPS leads to the regression of symptoms of depression, it also changes the concentration of thrombocyte serotonin and the mean volume of thrombocytes towards the values that reduce their role in pathogenesis of cardiovascular diseases, thus reducing the risk of re-occurrence of cardiovascular incidents and improving the patients’ recovery.

Ključne riječi
Serotonin; Thrombocytes; SIPPS; Depression; Cardiovascular diseases

Hrčak ID: 183313

URI
https://hrcak.srce.hr/183313

[hrvatski]

Posjeta: 277 *